Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Dr. Ezra Cohen on the Pharmacokinetics of Cabozantinib

September 30th 2012

Ezra E.W. Cohen, MD, from the University of Chicago Medical Center, on the pharmacokinetics and efficacy of cabozantinib for medullary thyroid cancer.

Dr. Sherman on Sequencing Cabozantinib and Vandetanib

September 28th 2012

Dr. Eric Sherman, Memorial Sloan-Kettering Cancer Center, on the optimal sequencing of cabozantinib and vandetanib for patients with medullary thyroid cancer.

Multikinase Inhibitor Prolongs Progression-Free Survival in MTC

September 25th 2012

Cabozantinib significantly prolonged progression-free survival in medullary thyroid cancer compared with placebo among patients with radiographically confirmed progressive disease at study onset.

Photos From the American Thyroid Association Annual Meeting

September 25th 2012

Photos from the 82nd Annual Meeting of the American Thyroid Association held in Quebec City, Canada, on September 19-23, 2012.

Dr. Sippel on the Importance of the Initial Surgery for MTC

September 25th 2012

Rebecca S. Sippel, MD, from the University of Wisconsin, discusses the importance of the initial surgery for patients with medullary thyroid cancer on outcomes.

Panels of Molecular Markers Improve Diagnosis of Thyroid Cancer

September 24th 2012

The application of molecular markers is already significantly improving the diagnosis of thyroid cancer and broader application could help prevent unnecessary surgeries to confirm the diagnosis.

BRAF Mutational Status in Papillary Microcarcinoma: Diagnostic and Prognostic Potential

September 24th 2012

Four histopathologic features of papillary microcarcinoma help predict how aggressive the tumor will be and subsequently how aggressive treatment must be to prevent its spread.

Dr. Haugen Describes the 82nd Annual ATA Meeting

September 21st 2012

Dr. Bryan Haugen, from University of Colorado School of Medicine, Describes the 82nd Annual Meeting of the American Thyroid Association.

Dr. Nikiforov on Molecular Testing of Thyroid Nodules

September 21st 2012

Dr. Yuri Nikiforov, from the University of Pittsburgh, on Molecular Testing to Diagnose Cancerous Thyroid Nodules.

Blanket Approach to RAI in PTC Patients May Not Be Necessary

September 21st 2012

A blanket approach to the use of radioactive iodine may not be necessary in many patients with papillary thyroid cancer provided they undergo expert total thyroidectomy first.

Disease Stabilization Now Possible in Metastatic MTC With Targeted Therapies

September 21st 2012

The availability of molecular agents that target oncogenic signaling pathways now offers the possibility of achieving disease stabilization in a proportion of patients with metastatic medullary thyroid cancer.

Initial Operation to Remove Medullary Thyroid Cancer Best Chance for Cure

September 21st 2012

The initial surgical procedure performed for the management of medullary thyroid cancer is the best chance surgeons have for a cure.

Study Will Evaluate Panitumumab Regimen in Advanced SCCHN

September 7th 2012

Canadian researchers are investigating standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy with panitumumab in locally SCCHN.

Cabozantinib Shows Promise as Potent RET Inhibitor in MTC

August 22nd 2012

The ability of cabozantinib to inhibit the RET pathway contributed to the pivotal clinical trial findings demonstrating that the novel oral agent significantly improved PFS in patients with advanced MTC.

A Patient Is His Own Best Advocate

August 15th 2012

Patients (and even clinicians) often don't know which facilities are considered leaders in the treatment of various types of cancer, and a bit of detective work is generally required.

Cabozantinib Submitted for FDA Approval After Positive Phase III Thyroid Cancer Trial

August 10th 2012

The tyrosine kinase inhibitor cabozantinib met its primary endpoint of progression-free survival in patients with advanced medullary thyroid cancer.

Dr. Cohen Discusses Treating Medullary Thyroid Cancer

July 26th 2012

Dr. Ezra Cohen, from the University of Chicago, Discusses Treating Medullary Thyroid Cancer

Erin McMenamin on Head and Neck Cancer Treatments

June 28th 2012

Erin McMenamin, MSN, Radiation Oncology, Hospital of the University of Pennsylvania, discusses treatments for HPV-positive head and neck cancer, which tends to have a better prognosis than HPV-negative head and neck cancers.

Dr. Kirkman on the Combination of PX-866 and Docetaxel

June 27th 2012

Dr. Robert Kirkman, the CEO of Oncothyreon, on the Combination of PX-866 and Docetaxel

Dr. Cohen Discusses the Cabozantinib EXAM Trial

June 13th 2012

Dr. Ezra Cohen, from the University of Chicago, Discusses the Cabozantinib (XL184) EXAM Trial